Claims for Patent: 9,675,617

Summary for Patent: 9,675,617

Title:	Tetrahydrofolates in combination with EGFR-inhibitors
Abstract:	The present invention relates a pharmaceutical composition comprising an EGFR inhibitor and methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate, for use in the treatment of cancer. The methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate enhances the anticancer efficacy of the EGFR inhibitor. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, esophageal cancer, mesothelioma cancer, lung cancer including non-small-cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, peripheral T-cell lymphoma (PTCL), melanoma, brain tumors, adenocarcinoma, esophageal cancer, and osteosarcoma.
Inventor(s):	Gustavsson; Bengt (Vastra Frolunda, SE), Carlsson; Bjorn (Vastra Frolunda, SE)
Assignee:	ISOFOL MEDICAL AB (Gothenburg, SE)
Application Number:	14/372,701
Patent Claims:	1. A method for the treatment of an EGFR-expressing cancer in a patient in need thereof, the method comprising administering to a patient a pharmaceutically active amount of a pharmaceutical composition comprising: a) methylene-tetrahydrofolate, and b) cetuximab; wherein said composition is administered in isolation of 5-fluorouracil and in isolation of analogues, prodrugs and/or metabolites of 5-fluorouracil. 2. The method according to claim 1, wherein component a) is administered no later than 24 hours before the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 3. The method according to claim 1, wherein component a) is administered no later than 36 hours before the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 4. The method according to claim 1, wherein component a) is administered no later than 48 hours before the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 5. The method according to claim 1, wherein component a) is administered at the earliest 6 hours after the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 6. The method according to claim 1, wherein component a) is administered at the earliest 24 hours after the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 7. The method according to claim 1, wherein component a) is administered at the earliest 48 hours after the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 8. The method according to claim 1, wherein component a) is administered at the earliest one week after the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 9. The method according to claim 1, wherein component a) is administered at the earliest 12 days after the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 10. The method according to claim 1, wherein said composition is administered no later than one week before the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 11. The method according to claim 1, wherein said composition is administered at the earliest one week after the administration of 5-FU and/or an analogue, prodrug and/or metabolite thereof. 12. The method according to claim 1, wherein said composition is administered in isolation from 5-FU and/or an analogue, prodrug and/or metabolite thereof during a time period of at least 3 months. 13. The method according to claim 1, wherein component a) and component b) are formulated in different pharmaceutical compositions. 14. The method according to claim 1, wherein component a) and component b) are formulated in a common pharmaceutical composition. 15. The method according to claim 1, wherein component b) is administered in an amount of at least 50 mg/m.sup.2 and at maximum 1000 mg/m.sup.2. 16. The method according to claim 1, wherein component a) is administered in an amount of at least 10 mg/m.sup.2 and at maximum 5 g/m.sup.2. 17. The method according to claim 1, wherein said cancer is selected from breast cancer, gastric cancer, gastrointestinal cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, esophageal cancer, mesothelioma cancer, lung cancer including non-small-cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, peripheral T-cell lymphoma (PTCL), melanoma, brain tumors, adenocarcinoma, esophageal cancer, and osteosarcoma. 18. A method for inhibiting tumor growth of an EGFR-expressing tumor in a patient in need thereof, the method comprising administering to a patient a pharmaceutically active amount of a pharmaceutical composition comprising methylene-tetrahydrofolate and cetuximab; wherein said composition is administered in isolation of 5-fluorouracil and in isolation of analogues, prodrugs and/or metabolites of 5-fluorouracil. 19. A method for reducing tumor volume of an EGFR-expressing tumor in a patient in need thereof, the method comprising administering to a patient a pharmaceutically active amount of a pharmaceutical composition comprising methylene-tetrahydrofolate and cetuximab; wherein said composition is administered in isolation of 5-fluorouracil and in isolation of analogues, prodrugs and/or metabolites of 5-fluorouracil.

Details for Patent 9,675,617

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2032-01-20
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2032-01-20